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1. Introduction
The use of models estimating the dosage delivered to a lung region to help design delivery
systems for new drugs is well established (e.g. Finlay et al. (1997)). This approach, also called
in silico testing, however has not yet received regulatory acceptance (Forbes et al. (2011)). A far
less common application of lung deposition models is in the estimation of the concentration
of the inhaled drug in the liquid layer that coats the human airways, also know as the airway
surface liquid (ASL).
One case when the lung concentration of the inhaled drug is more relevant than the total
deposited dosage is in the treatment of the effects of cystic fibrosis. To enhance themucociliary
clearance and to promote normal lung function in cystic fibrosis patients, mucolytic agents
have been developed for aerosol delivery to the lung. These drug compounds are considered
topically active, since their efficacy depends on reaching a proper concentration level, as
determined by in vitro and ex vivo experiments. When designing clinical trials and treatment
protocols, the total dosage delivered by inhalation needs to ensure that such concentration
levels are reached in the mucus layer in each lung generation.
With the continuing emergence of multiply antibiotic-resistant organisms, the need to develop
new, more powerful antibiotics remains evident. For determining an effective dose of a
new antibiotic, it is common practise to use a series of clinical trials with different doses
of the new drug starting from a small amount and moving to higher amounts gradually.
However, resource limitations sometimes constrain the initial trial to a single dose, imposing
the condition that this single attempt be effective before additional funds are made available.
A requirement for efficacy of antibiotics is that the in vivo drug concentration be sustained at
a level that ensures minimum inhibitory concentration (MIC), since otherwise resistance may
be promoted.
Antibiotics and mucolytics are drugs that exhibit concentration dependence in their efficacy.
Therefore, ensuring appropriate concentration of these drugs in the relevant body fluid is
important for obtaining the desired therapeutic and physiological result. Until recently there
had been no suitable method available to predict the amount of inhaled drug required to
ensure efficacious concentration levels in the airway surface liquid (ASL).
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Now, the combination of a lung deposition model with a novel model of the ASL layer
allow for an estimate of the local average drug concentration in each lung generation k after
inhalation
Ck,ASL =
mk,drug
(Vk,ASL + Vk,aerosol)
(1)
The main focus of this chapter is to present a recently developed model that estimates local
concentration of inhaled pharmaceutical aerosols in the ASL and to explain, with examples,
how such amodel can assist in the development of new inhaled drugs that are topically active,
i.e. that depend on reaching proper concentration levels locally in the lung. Examples of recent
use of this model are Desai et al. (2003); Sweeney et al. (2005); Wang et al. (2003).
2. Modelling drug deposition in the lung
To estimate the local concentration of a drug in the lung, it is necessary to estimate first the
amount of drug deposited in each lung generation.
The modelling of deposition of inhaled aerosols over the years has evolved from simple
and limited algebraic models (James et al. (1991)) to more complex and accurate empirical
(Martonen et al. (1994)), one-way coupled (Ferron et al. (1988)), and two-way coupled
hygroscopic models (Finlay & Stapleton (1995)), based on the Lagrangian approach. All
these models treat the lung as unidimensional, calculating deposition on a typical or average
aerosol path. While Lagrangian models can well represent the inhalation and deposition from
continuous nebulizers, single breath inhalers and smart nebulizers derive their enhanced
performance from time dependent effects that can only be accurately captured by Eulerian
models. Eulerian deposition models have been available for many years (Egan & Nixon
(1985); Roth et al. (2003); Taulbee & Yu (1975)) and recently have also incorporated one-way
coupled hygroscopicity (Mitsakou et al. (2005)). However, they have not found widespread
use, probably because of the relative complexity of their implementation.
The application of Computational Fluid Dynamics (CFD) to model aerosol deposition in a
three-dimensional representation of the airways is relatively recent. Initially, the simulations
were constrained to specific stretches of the airway path, such as the trachea and a few
generations of the lung, or the alveolar region (Dailey & Ghadiali (2007)). These simulations
offer some insight into the local effects of geometry on the flow, such as the tracheal rings,
the shape of the carinal ridge or the size change of the alveoli. However, these analyzes are
limited by the lack of upstream information about the flow.
Of all components required to predict lung deposition, arguably the most important and most
challenging is the correct prediction of extrathoracic losses. These losses, compounded by
inhalability losses in the case of infants and small children using masks, define the dosage
actually delivered to the lung, assuming the device output is known. As DeHaan & Finlay
(2001; 2004) demonstrated with dry powder inhalers, extrathoracic deposition can depart
quite significantly from the baseline case of particles inhaled from a smooth, wide, straight
tube with approximately constant inhalation rate studied by Stahlhofen et al. (1983). While
we now understand much better the flow and deposition mechanisms occurring in the
oropharyngeal region following the analysis of Heenan et al. (2004), the large scatter
of data caused by intersubject variabilities even during controlled inhalation conditions
(Stahlhofen et al. (1983)) would preclude any accurate prediction of extrathoracic losses.
Fortunately, a comprehensive study of the effects of intersubject variability by Grgic et al.
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(2004) led to the discovery of a universal form of the Stokes parameter allowing for a more
accurate prediction of the oropharyngeal deposition in a wide variety of realisticmouth-throat
geometries. This mathematical relationship can potentially be used to predict lung dosages
from inhalers, instead of the currently used delivered dose.
One-dimensional, dynamical lung deposition models, though heavily simplified with respect
to the airway geometry, can incorporate all the fundamental physical processes that affect
particle size and deposition at a small fraction of the computational effort of CFD. Naturally,
these 1-D models cannot resolve local deposition patterns, such as required by a tumour,
but they can be properly tuned to give accurate results for delivery of drugs that target
an entire lung region. The treatment of lung diseases associated with cystic fibrosis,
such as bacterial infections and mucolytic treatments, are examples of cases that target a
single lung region, namely the tracheobronchial region. Advanced one-dimensional models
can provide this regional deposition information with high accuracy, as demonstrated by
Finlay, Lange, Li & Hoskinson (2000). For these reasons, 1-D models seem better suited for
the use in the modelling of local concentration of deposited drugs in the lung.
3. Modelling mucus and the Airway Surface Liquid layer
Themodel of the Airway Surface Liquid (ASL) layer, developed at the University of Alberta by
the author in collaboration with W. Finlay and M. King (Finlay, Lange, King & Speert (2000);
Hasan & Lange (2007); Lange et al. (2001)) is the first and, to this date, the only model of its
kind. The model approximates the amount of liquid matter present in each lung generation,
which, in conjunction with the local dosage provided by the deposition model, allows for the
estimate of the local concentration of the inhaled drug.
A previous attempt to estimate concentration of deposited aerosols was performed by
Böhm et al. (2003). They used an empirical estimate of lung deposition and a simple
assumption of a constant thickness of the ASL layer in a single generation. An approach closer
to the one proposed here was employed by Kimmel et al. (2001) to study transient clearance
and mucus concentration in rats. But the mucus layer thickness was considered constant
throughout the tracheobronchial region.
The ASL model distinguishes two layers with essentially different physical properties: the
periciliary liquid layer (PCL), a watery layer (sol) covering the airway epithelium, and the
mucus layer, a viscoelastic gel that floats on top of the PCL (see Fig. 1).
The volume of liquid in each layer is modelled separately. The sum of the two gives the
total ASL volume in each generation, Vk,ASL. For the calculation of the volume we assume
a continuous annular layer of liquid along each generation. Figure 2 shows a schematic
cross-sectional view of an airway.
The dimensions of the airways are obtained from the lung geometry model by Finlay
(2001), which has been shown to correlate well with in vivo regional deposition experiments
(Finlay, Hoskinson & Stapleton (1998)). The geometry assumes a symmetric branching airway
system, starting from the extrathoracic region (mouth cavity, pharynx and larynx), followed
by the trachea, and branching symmetrically into two main bronchi, then into four lobar
bronchi, and so on. Each new branch segment is called a generation, k. The trachea is
considered the first generation (k = 0), and the main bronchi are k = 1, so that the number of
airways in each generation is always 2k.
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Fig. 1. Schematic of the airways with ASL layer and mucociliary escalator.
Fig. 2. Airway cross-section with PCL and mucus layers.
In contrast with the classical lung model, Weibel A (Weibel (1963)), which considers
generations 0–16 to form the tracheobronchial region, Finlay’s model sets the transition
between the tracheobronchial region and the more distal alveolar region at the generation
14. This distinction is relevant, because mucociliary transport exists only in the conductive
airways, starting at the terminal bronchioles, which are the most distal ciliated airways. While
the calculation of the deposited dosage, described above, utilizes the complete lung geometry,
the ASL layer is only defined in the tracheobronchial region. The dimensions of the airways
in each tracheobronchial generation are reproduced from Finlay (2001) in Table 1.
The ASL model uses the same average airway diameter and length in generation k as the
deposition model, Dk and Lk. With these geometric characteristics, the volume of ASL in
generation k can be calculated as
Vk,ASL = pi Lk 2
k
(
Dk hk,ASL − h
2
k,ASL
)
(2)
where the thickness of the ASL layer, hk,ASL, needs to be determined and is defined as
hk,ASL = hk,PCL + hk,ML (3)
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Generation Length [cm] Diameter [cm]
0 12.456 1.810
1 3.614 1.414
2 2.862 1.115
3 2.281 .885
4 1.780 .706
5 1.126 .565
6 .897 .454
7 .828 .364
8 .745 .286
9 .653 .218
10 .555 .162
11 .454 .121
12 .357 .092
13 .277 .073
14 .219 .061
Table 1. Airway dimensions in the tracheobronchial tree (from Finlay (2001)).
i.e., it is the sum of hk,PCL and hk,ML, the thicknesses of the PCL andmucus layers, respectively.
In certain cases, such as in the inhalation of mucolytics, it is the volume of mucus only that is
required. In this case, the same assumptions as above give
Vk,ML = pi Lk 2
k
(
Dk,red hk,ML − h
2
k,ML
)
(4)
where Dk,red is the airway diameter reduced by the PCL layer thickness
Dk,red = Dk − 2 hk,PCL (5)
Since the airway geometry follows the deposition model and is known, all that is required to
estimate the volumes of mucus and ASL are the layer thicknesses. In the following sections
the calculation of the PCL and mucus layer thicknesses is described.
3.1 Thickness of PCL layer
The PCL layer is formed by a watery liquid that facilitates the beating of the cilia and keeps the
thicker mucus layer afloat at an exact distance to be reached by the tip of the cilia during their
forward beating (Widdicombe (1997)). Although the regulation mechanism of the PCL layer
thickness in the airways is still the subject of controversy (Matsui et al. (1998)), it is recognized
that this regulated thickness is well approximated by the length of the cilia.
Measurements of cilia lengths in humans were performed by Serafini & Michaelson (1977)
and are given in Table 2.
Two curve fits were tested to approximate the Serafini and Michaelson measurements with a
smooth curve along the entire tracheobronchial region. The fitted functions that estimate the
cilia length at generation k, and by extension the thickness of the PCL layer, are
hk,PCL = 5.911 e
−k/13.4048 (fit1) (6)
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Generation Length [µm]
0 6.03
3 4.70
5 3.87
6 3.72
7 3.60
Table 2. Human ciliary length in various lung generations from measurements.
Fig. 3. Experimental and curve fitted values of cilia length in humans.
Generation hk,PCL [µm]
0 6.04
1 5.49
2 5.02
3 4.61
4 4.27
5 3.99
6 3.74
7 3.53
8 3.36
9 3.21
10 3.08
11 2.97
12 2.88
13 2.81
14 2.74
Table 3. Human ciliary length and PCL thickness in various lung generations.
hk,PCL = 2.3717+ 3.6724 e
−k/6.0837 (fit2) (7)
A plot of the raw data and of both curves can be seen in Fig. 3.
Curve fit “fit2” was selected as best fit and the corresponding values of thickness of the PCL
layer, based on eq. 7 above, are shown in Table 3.
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3.2 Mucus layer thickness
The mucus layer is essentially a gel formed by secretions from goblet cells located in the
airway epithelium and also from submucosal glands in the larger airways (Widdicombe
(1997)). The thickness of the mucus layer is estimated assuming a continuous layer of constant
thickness in each generation, using mass conservation, and modelling the average mucus
velocity and production rate for each generation.
The mucus layer is constantly driven by the coordinated beating of airway cilia from the distal
generations to the trachea forming the so-called mucus escalator, as illustrated in Fig. 1. The
14th generation is assumed to be the most distal tracheobronchial generation, as described
above, where mucus production starts. In reality, as there is no sharp transition from the
alveolar region to the tracheobronchial region, the mucus production also does not start
always at the 14th generation. In addition, in the more distal generations the mucus layer
is not yet fully continuous, but there are probably patches of mucus until the cumulative
production ensures full coverage of the airways. For lack of a better alternative, the present
model assumes that mucus production starts at generation 14 and forms a continuous annular
layer from the onset.
Mucus is actually continuously produced along the conductive airways. The amount
produced at a generation k joins the cumulative amount produced at all previous (more
distal) generations up to that generation, as the mucus is transported towards the trachea.
The amount of mucus that flows through generation k is the accumulated amount produced
up to this point, i.e. the sum of all mucus produced by generations k + 1 to 14, plus the locally
produced amount (p˙k). This local total production is called P˙k.
The flow rate of mucus through all airways of a generation is equal to the product of the
annular cross-sectional area of the mucus layer, Ak,ML, and the mucociliary transport velocity
at this generation (clearance velocity), Uk, i.e.
P˙k = Ak,ML Uk = 2
k
pi
(
Dk,red hk,ML − h
2
k,ML
)
Uk (8)
where Dk,red is defined in eq. 5, and the cumulative production rate P˙k at generation k is
defined by the recursive formula
P˙k = p˙k + P˙k+1 (9)
where p˙k is the local production rate at generation k. The estimates of p˙k are described below
in section 3.3.
Equation 8 is a quadratic polynomial in terms of hk,ML
2k pi Uk h
2
k,ML − 2
k
pi Uk Dk,red hk,ML + P˙k = 0 (10)
whose only physical solution is
hk,ML =
2k piUk Dk,red −
√
(2k pi Uk Dk,red)
2
− 4 (2k)piUk P˙k
2 (2k)pi Uk
(11)
Rearranging the terms and defining the reduced airway radius corresponding to Rk,red =
Dk,red/2, eq. 11 can be rewritten
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hk,ML = Rk,red −
√
R2k,red −
P˙k
2k piUk
(12)
Hence, the average thickness of the mucus layer in a generation can be determined, if the
cumulative production up to that generation (P˙k) and the local clearance velocity (Uk) are
known. Their determination in this model is described in the following sections.
Equation 12 provides also a condition to test for airway clogging. If the result from the two
terms inside the square root is negative, this means that the clearance velocity is too slow
to transport the required mucus flow rate through the whole airway cross-section, which
would cause the airways to clog. Although airway clogging actually occurs in severe disease
states, the present model is not designed to deal with clogging and parameter sets resulting
in clogging should be disregarded.
3.3 Distributed mucus production
For the distribution of the mucus production along the conducting airways there are no
human data currently available. As an approximation for the distribution of mucus secretion
in humans, the airway surface density of total secretory material measured by Plopper et al.
(1989) in various lung generations of the rhesus monkey was adopted. The rhesus monkey is
considered in many aspects one of the animals closest to humans, and their similarity in terms
of airway surface morphology is well established (Jeffery (1983)).
The volume of total secretory product in the surface epithelium and in submucosal glands
per unit airway area measured by Plopper et al. (1989) in specific generations of the monkey’s
lung was as shown in Table 4.
Generation Total
0 3.671
3 4.179
6 3.086
11 2.169
13 1.039
15 0.656
Table 4. Distribution of total mucus secretory product in rhesus monkey [×10−3 mm3/mm2]
(from Plopper et al. (1989)).
By assuming that the total secretory product per unit airway area is proportional to the
amount actually produced per unit area, and by assuming these values scale to humans
simply with the airway surface area, i.e. the same rates per unit area apply, these distributed
rates were transferred and directly applied to the human lung model. To obtain intermediate
values for the missing generations, two straight lines were fit to the data. The first curve fit
was a simple interpolation between the first two points. For the second curve fit the value
at generation 15 was disregarded. Not only is generation 15 beyond the assumed end of the
tracheobronchial region, but also its inclusion would cause the resulting curve fit to end too
abruptly at generation 14. With the actual, adjusted values shown in Table 5 the resulting
curve tends to zero at generation 16, which agrees better with the adopted lung model (see
Fig. 4).
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Fig. 4. Distributed mucus production (volumetric surface production [×10−3 mm3/mm2])
and curve fits (eqs. 13 and 14).
Generation Adjusted Surf. Production
0 3.671
3 4.179
6 3.086
11 2.169
13 1.039
15 0.000
Table 5. Distribution of volumetric mucus production in humans [×10−3 mm3/mm2].
The fitted curves shown in Fig. 4 and used to calculate the distributed local mucus production
per unit area p˙′′k correspond to the following functions
For generations 0 – 3: p˙′′k = 0.1693 k + 3.671 (13)
For generations 3 – 14: p˙′′k = −0.3238 k + 5.203 (14)
where k is the generation and the result is in ×10−3 mm3/mm2. Table 6 shows the
corresponding values in each generation.
The distributed local mucus production per unit area p˙′′k is combined with the dimensions of
the adopted lung geometry model to result in reference values of average mucus production
rates in each generation, according to the following equation
p˙k,ref = p˙
′′
k
(
2k pi Lk Dk
)
(15)
Equation 15 combined with eq. 9 result in a reference profile of distributed mucus production
in the airways, P˙k,ref. Since the production rate of mucus varies from person to person and can
also vary with time for the same individual, this reference profile of mucus production is used
to scale the actual production profile according to the value of actual total daily production
of the subject, P˙tot. A reasonable daily production amount for a healthy, non-smoking adult
is 10 ml/day. Typically, a range of values is used in the calculations with 5 ml/day being a
reasonable minimum for an adult, and 30 ml/day or greater being considered hypersecretion,
481Improving the Likelihood of Success in Trials and the Efficiency of Del very of Mucolytics and Antibiotics
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Generation Surface Production
0 3.67
1 3.84
2 4.01
3 4.18
4 3.91
5 3.58
6 3.26
7 2.94
8 2.61
9 2.29
10 1.97
11 1.64
12 1.32
13 0.99
14 0.67
Table 6. Distribution of volumetric mucus production p˙′′k in humans [×10
−3 mm3/mm2].
requiring therapy (Hardy & Anderson (1996)). In fact, patients with severe bronchorrhea have
been reported to produce in average more than 60 ml/day (Tamaoki et al. (1994)).
The actual cumulative production values are obtained by modifying the reference values
with a scaling factor, namely the ratio between the prescribed total daily production and the
cumulative reference production at the trachea (gen. 0)
P˙k =
(
P˙tot
P˙0,ref
)
P˙k,ref (16)
Equation 16 provides the actual cumulative production required in eq. 12.
3.4 Mucus clearance velocity
The airway mucus is a highly viscoelastic fluid that is transported by the lung clearance
mechanism (cilia beating) from the terminal bronchioli to the trachea. Due to its viscoelasticity,
the mucus forms a continuous layer that flows with almost no mixing. Inhaled particles
trapped in this layer are transported smoothly and continuously towards the trachea, where
they are swallowed. This mucociliary clearance process can be treated as a series of
“escalators” that transport mucus and whatever it is carrying from one generation to the next
with constant velocity within each generation.
If a tracer substance is inhaled and its clearance measured, the time to clear the trachea
(the first generation to be cleared) would be τ0 = L0/U0, where U0 is the constant mucus
transport velocity at the trachea. The amount of tracer deposited in the main bronchi, the next
generation to be cleared, would require the time to travel through the bronchi, τ1 = L1/U1,
plus the time to travel through the trachea τ0 to be cleared. This process is illustrated in Fig. 5.
In general, measuring from the time when the first particles deposited in generation k begin
482 Cystic Fibrosis – Renewed Hopes Through Research
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Fig. 5. Schematic of the mucociliary escalator.
to be cleared until the time when the last particles from that generation are cleared results in
k
∑
i=0
τ i −
k−1
∑
j=0
τ j =
k
∑
i=0
Li
Ui
−
k−1
∑
j=0
Lj
Uj
=
Lk
Uk
= τk (17)
By combining cumulative deposition data from the lung deposition model and the in vivo
clearance data from Stahlhofen et al. (1980) the time τk required to clear each generation was
determined. Fig. 6 illustrates this process.
Fig. 6. Time to clear generation k obtained from comparison between cumulative deposition
and clearance data.
Four cases measured by Stahlhofen et al. (1980) (breathing pattern A (op. cit., Fig. 8): subject
1 and da=9.5 µm, subject 4 and da=9.1 µm; breathing pattern B (op. cit., Fig. 9): subject 1
and da=7.5 µm, subject 4 and da=7.3 µm) were calculated with the 1-D deposition model from
Finlay & Stapleton (1995), using the lung geometry dimensions from Finlay (2001). Note that
the length of the trachea was shortened by 3 cm, because of the way the tracheobronchial
region was imaged in Stahlhofen et al. (1980). The resulting velocity profiles were scaled
with a reference clearance velocity at the trachea (U0,ref = 5.5 mm/min) and averaged so
that a standard reference clearance velocity profile was generated. This reference profile of
483Improving the Likelihood of Success in Trials and the Efficiency of Del very of Mucolytics and Antibiotics
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mucus transport velocities in each generation (Uk,ref) is shown in Table 7. Figure 7 shows
a comparison of the present reference velocity profile with other similar profiles estimated
by Lee et al. (1979), Yu et al. (1986) and Cuddihy & Yeh (1988). All profiles were scaled to a
tracheal clearance velocity of 5.5 mm/min.
Fig. 7. Comparison of clearance velocity profiles (all profiles scaled to U0=5.5 mm/min).
Generation Clearance Velocity
0 5.5000
1 1.3415
2 0.9943
3 0.7439
4 0.5477
5 0.3425
6 0.2551
7 0.2073
8 0.1554
9 0.1063
10 0.0667
11 0.0389
12 0.0206
13 0.0092
14 0.0056
Table 7. Clearance velocity profile (Uk,ref in [mm/min], constant in each generation).
Similarly to the variability in the daily mucus production rate, the clearance velocity also
shows variation between individuals and for a single individual, depending on their physical
activity, for instance. The linear velocity of mucus flow in the trachea in young nonsmokers
has been measured by marker particle clearance as typically 10–15 mm/min (Wanner et al.
(1996)). CF patients have been assessed with tracheal clearance velocities that range from
essentially zero up to these normal values Yeates et al. (1975).
Here again the actual clearance velocities used in the model are obtained by scaling the entire
profile with the ratio between the prescribed tracheal velocity U0,set and the reference value
U0,ref as follows
Uk =
(
U0,set
U0,ref
)
Uk,ref (18)
484 Cystic Fibrosis – Renewed Hopes Through Research
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Equation 18 provides the actual clearance velocities required in eq. 12.
Using the clearance velocity profiles shown in Fig. 7 and a distributed mucus production
based on eqs. 13 and 14, scaled to a total of 10 ml/day, a comparison of estimated mucus layer
thicknesses can be calculated. The results are shown in Fig. 8.
Fig. 8. Comparison of mucus layer thicknesses based on clearance velocities from Fig. 7 and
10 ml/day distributed production.
Combining the thicknesses of the mucus and the PCL layers, the total volume of ASL in each
generation can be finally calculated using eq. 2.
4. Modelling local lung concentration of topically active drugs
Once the mass of drug deposited in each generation is obtained with the aerosol deposition
model, and the volume of ASL in each generation is obtained with the ASL model, local
concentration values can be estimated.
Pharmaceutical aerosols are often an aqueous solution or suspension and the water they
carry contributes to the dilution of the drug in the ASL. In addition to knowing the mass
of drug deposited in each generation, mk,drug, it is important to also keep track of the mass
of water deposited together with the drug, mk,water. If the aerosol is hygroscopic, evaporation
may take place in the first few generations and condensation may occur deeper in the more
distal airways. The deposition model should account for these changes. We can convert the
deposited mass of drug and water to the corresponding volume of deposited aerosol, using
Vk,aerosol =
mk,drug
ρeff
+
mk,water
ρwater
(19)
where ρeff and ρwater are the effective density of the drug formulation and of water,
respectively.
All the required information is now available to estimate the average concentration of the
drug in the mucus layer, Ck,ML, or in the total ASL layer, Ck,ASL, in each generation
Ck,ML =
mk,drug
(Vk,ML + Vk,aerosol)
(20)
Ck,ASL =
mk,drug
(Vk,ASL + Vk,aerosol)
(21)
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To account for inter-subject variability and other uncertainties, ranges of physiological values
should be used, resulting in minimum and maximum expected concentration values. Table 8
lists a range of physiological values that can be used.
unit Min. Nominal Max.
Tracheal Clearance Velocity mm/min 5 10 to 15 20
Daily Mucus Production ml/day 5 10 60
Table 8. Range of physiological values of input quantities to the model.
The result of the model is a series of concentration curves for each scenario. These local
concentrations are then compared with efficacy levels and toxicity levels of the drug, to verify
if they are within those limits. The type of delivery device and the prescribed dosage can
be adjusted to optimize the predicted concentration levels, thus increasing the likelihood of a
successful outcome.
5. Advances in delivery devices
Recent advances of drug delivery devices have increased substantially their efficiency and
their ability to adjust the dose delivered to the lung. From the low cost vented jet nebulizers
to the more sophisticated breath-actuated, also known as smart nebulizers, the current
generation of inhalers allows for the efficient delivery of large doses with an increasing ability
to control the amount delivered. Both aspects are important when delivering antibiotics to the
lung. Efficient delivery of a large dose may be required to ensure MIC levels are reached. At
the same time, control over the dosage is required to ensure that toxicity levels of the antibiotic
are not exceeded.
Despite the development of competing types of devices for drug delivery to the lung,
from metered dose inhalers to dry powder inhalers, jet nebulizers have never been
completely replaced. They are still capable of delivering the largest dosages to the lung.
The ability to contain high volume fills makes them uniquely adapted for this purpose.
Many types of continuous output nebulizers are on the market today. Among them,
valved vented (also called breath enhanced) jet nebulizers reduce the amount of drug lost
during exhalation by delivering aerosol preferentially during inhalation. Less affordable,
but more compact, ultrasonic nebulizers find widespread use in many clinical settings.
Finlay, Stapleton & Zuberbuhler (1998) compared various traditional nebulizers and found a
large variation in the predicted lung dosage between the devices.
Nebulizers have experienced a revival through the introduction of so-called “smart
nebulizers” (Smaldone (2002)). This is a relatively informal classification that includes all
the liquid atomizers, which either use or control the breathing pattern for targeted drug
delivery. The technologies used for liquid atomization may vary, but these smart nebulizers
have in common the attempt to link aerosol generation with the patient inhalation. Examples
of smart nebulizers based on jet nebulization are the breath actuated AeroEclipse® (MMC),
the Prodose AAD® System (Profile/Respironics), and the AKITA® system (InAMed). Other
smart nebulizers or liquid atomizers use different nebulization technologies. Aerodose®
(Aerogen) and eFlow® (Pari) are examples of vibrating orifice based nebulizers, which are
capable of more precise dosing. All these new devices incorporate breath actuation and some
level of drug delivery control and feedback. Ideally, these monitoring capabilities of the
delivered dosage and control of aerosol emission in smart nebulizers could be coupled with
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an embedded processing unit that estimates the actual deposited dose in the lung, allowing
for individually adjusted treatment with the highest probability of successful outcome, as
suggested by Lange & Finlay (2006).
This desirable ability to ensure that a prescribed dosage is effectively delivered to the lung is
particularly important in the case of antibiotic treatment of lung infections in cystic fibrosis, to
reduce the risk of promoting drug resistance through low concentration levels of antimicrobial
in the ASL.
6. Applications of the model
The ASL concentration model described above could be in the future incorporated into the
control and feedback systems of smart nebulizers, coaching individual patients to inhale the
precise dosage required to reach the MIC as estimated by the model.
Currently, the ASL concentration model can be of vital assistance to the design of clinical
trials to increase the chances of a positive outcome by ensuring proper concentration levels
are achieved in the lung during the tests. An example of how this model can be used to
improve the outcome of clinical trials was described byHasan & Lange (2007). Two antibiotics
were compared, using data from the literature. One of the two was tobramycin, an inhaled
antibiotic, which is widely used by CF patients. The other example was taurolidine, which
was considered for use against B. cepacia in CF patients, but failed to produce results in its first
clinical trial with delivery by inhalation.
Using the same input parameters described in Hasan & Lange (2007) for the case of
tobramycin, corresponding to the study of Ramsey et al. (1999), the estimates of ASL
concentration of the antibiotic were recalculated with increased accuracy by taking into
account hygroscopic effects in the aerosol size distribution. The new estimates, shown
in Fig. 9, result in slightly increased concentrations, which confirm the prediction that
concentration levels well exceeded the value of 0.08 mg/mL, or ten times higher than the in
vitro MIC value, recommended for in vivo efficacy against P. aeruginosa. These concentration
levels were predicted for all 16 scenarios within the range of input parameters studied, while
Fig. 9 only shows a few representative cases, including the maximum and minimum curves
of the range.
A different outcome befell a clinical trial of taurolidine, a promising drug candidate
against P. aeruginosa and B. cepacia in CF. The outcome of the randomized double-blinded
placebo-controlled crossover trial by Ledson et al. (2002), showed no improvement in sputum
B. cepacia colony counts. As a consequence of this result, development of the inhaled form of
this new drug was halted.
Using model input data that matched as closely as possible the study by Ledson et al. (2002),
the above-described model estimated ASL concentration levels that in many cases did not
exceed the in vitro MIC values of 0.4 mg/mL (see Fig. 10), when it is known that in vivo
concentrations need to be much higher for successful antimicrobial effect.
The higher end of the predictions reached approximately 5 times the in vitro MIC, but this
scenario (high mucociliary clearance velocity and low mucus production) corresponds more
likely to a non-CF patient, such as the single case reported by Ledson et al. (2000). Taking this
higher concentration (2 mg/mL) as a new required level, one could use the ASL concentration
model to help design a hypothetical trial that would ensure such levels were reached in the
487Improving the Likelihood of Success in Trials and the Efficiency of Del very of Mucolytics and Antibiotics
www.intechopen.com
16 Will-be-set-by-IN-TECH
Fig. 9. Estimated ASL concentration of tobramycin in clinical trial.
Fig. 10. Estimated ASL concentration of taurolidine in clinical trial.
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majority of the cases. Figure 11 demonstrates such a scenario, which could be achieved with
a slightly larger nebulizer fill and a significantly larger concentration of taurolidine in the
solution.
Fig. 11. Estimated ASL concentration of taurolidine in a hypothetical trial that were
designed with assistance of the ASL concentration model.
Although a new trial design with higher ASL concentrations would still not be guaranteed to
succeed, it would at least stand a better chance of a positive outcome that would allow the
continuation of the new drug development.
We conclude that the ASL concentration model is an important tool in the design of clinical
trials of inhaled drugs that require a certain concentration level in the lung mucus or the ASL
for efficacy.
Similarly, in later stages of the development of a new inhaled drug, the ASL concentration
model can greatly assist in the selection of the most appropriate drug delivery device and in
establishing the most adequate treatment protocols.
7. Acknowledgements
The mucus and ASLmodels were developed by the author under the supervision of W. Finlay
and in close collaboration with M. King. Their contribution is gratefully acknowledged.
8. References
Böhm, R., Nikodemova, D. & Holy, K. (2003). Use of various microdosimetric models
for the prediction of radon induced damage in human lungs, Radiat. Prot. Dosim.
104(2): 127–137.
Cuddihy, R. G. & Yeh, H. C. (1988). Respiratory tract clearance of particles and substances
dissociated from particles, Springer, Berlin, chapter 11, pp. 169–193.
489Improving the Likelihood of Success in Trials and the Efficiency of Del very of Mucolytics and Antibiotics
www.intechopen.com
18 Will-be-set-by-IN-TECH
Dailey, H. L. & Ghadiali, S. N. (2007). Fluid-structure analysis of microparticle transport in
deformable pulmonary alveoli, J. Aerosol Sci. 38: 269–288.
DeHaan, W. H. & Finlay, W. H. (2001). In vitro monodisperse aerosol deposition in a mouth
and throat with six different inhalation devices, J. Aerosol Med. 14(3): 361–367.
DeHaan, W. H. & Finlay, W. H. (2004). Prediciting estrathoracic deposition from dry powder
inhalers, J. Aerosol Sci. 35(3): 309–331.
Desai, T. R., Tyrrell, G. J., Ng, T. & Finlay, W. H. (2003). In vitro evaluation of nebulization
properties, antimicrobial activity and regional airway surface liquid concentration of
liposomal polymyxin B sulfate, Pharm. Res. 20: 442–447.
Egan, M. J. & Nixon, W. (1985). A model of aerosol deposition in the lung for use in inhalation
dose assessments, Radiation Protection Dosimetry 11(1): 5–17.
Ferron, G. A., Kreyling, W. G. & Haider, B. (1988). Inhalation of salt aerosol particles – II.
Growth and deposition in the respiratory tract, J. Aerosol Sci. 19(5): 611–631.
Finlay,W.H. (2001). The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction, Academic
Press, London.
Finlay, W. H., Hoskinson, M. & Stapleton, K. W. (1998). Can models be trusted to subdivide
lung deposition into alveolar and tracheobronchial fractions?, Respiratory Drug
Delivery VI, Interpharm Press, Buffalo Grove, IL, USA, pp. 235–242.
Finlay, W. H., Lange, C. F., King, M. & Speert, D. P. (2000). Lung delivery of aerosolized
dextran, Am. J. Respir. Crit. Care Med. 161: 91–97.
Finlay, W. H., Lange, C. F., Li, W.-I. & Hoskinson, M. (2000). Validating deposition models in
disease: what is needed?, J. Aerosol Med. 13: 381–385.
Finlay, W. H. & Stapleton, K. W. (1995). The effect on regional lung deposition of coupled
heat and mass transfer between hygroscopic droplets and their surrounding phase,
J. Aerosol Sci. 26(4): 655–670.
Finlay, W. H., Stapleton, K. W. & Zuberbuhler, P. (1997). Predicting regional lung dosages of a
nebulized suspension: Pulmicort® (budesonide), Part. Sci. Technol. 15: 243–251.
Finlay, W. H., Stapleton, K. W. & Zuberbuhler, P. (1998). Variations in predicted regional
lung deposition of salbutamol sulphate between 19 nebulizer models, J. Aerosol Med.
11: 65–80.
Forbes, B., Asgharian, B., Dailey, L. A., Ferguson, D., Gerde, P., Gumbleton, M., Gustavsson,
L., Hardy, C., Hassall, D., Jones, R., Lock, R., Maas, J., McGovern, T., Pitcairn, G. R.,
Somers, G. & Wolff, R. K. (2011). Challenges in inhaled product development and
opportunities for open innovation, Adv. Drug Deliv. Rev. 63: 69–87.
Grgic, B., Finlay, W. H., Burnell, P. K. P. & Heenan, A. F. (2004). In vitro intersubject and
intrasubject deposition measurements in realistic mouth-throat geometries, J. Aerosol
Sci. 35(1): 1025–1040.
Hardy, K. A. & Anderson, B. D. (1996). Noninvasive clearance of airway secretions, Respir.
Care Clin. N. Am. 2: 323–345.
Hasan, M. A. & Lange, C. F. (2007). Estimating in vivo airway surface liquid concentration in
trials of inhaled antibiotics, J. Aerosol Med. 20(3): 282–293.
Heenan, A. F., Finlay, W. H., Grgic, B., Pollard, A. & Burnell, P. K. P. (2004). An investigation
of the relationship between the flow field and regional deposition in realistic
extra-thoracic airways, J. Aerosol Sci. 35: 1013–1023.
James, A. C., Stahlhofen, W., Rudolf, G., Egan, M. J., Nixon, W., Gehr, P. & Briant, J. K. (1991).
The respiratory tract deposition model proposed by the ICRP task group, Radiation
Protection Dosimetry 38(1): 159–165.
490 Cystic Fibrosis – Renewed Hopes Through Research
www.intechopen.com
Improving the Likelihood of Success in Trials and the Efficiency of Delivery of Mucolytics and Antibiotics 19
Jeffery, P. K. (1983). Morphologic features of airway surface epithelial cells and glands, Am.
Rev. Respir. Dis. 128: S14–S20.
Kimmel, E. C., Reboulet, J. E. & Carpenter, R. L. (2001). A typical path model of
tracheobronchial clearance of inhaled particles in rats, Toxicol. Ind. Health 17: 277–284.
Lange, C. F. & Finlay, W. H. (2006). Liquid atomising: nebulizing and other methods of
producing aerosols, J. Aerosol Med. 19(1): 28–35.
Lange, C. F., Hancock, R. E. W., Samuel, J. & Finlay, W. H. (2001). In vitro aerosol delivery
and regional airway surface liquid concentration of a liposomal cationic peptide, J.
Pharm. Sci. 90(10): 1647–1657.
Ledson, M. J., Cowperthwaite, C., Walshaw, M. J., Gallagher, M. J., Williets, T. & Hart, C. A.
(2000). Nebulized taurolidine and B. cepacia bronchiectasis, Thorax 55: 91–93.
Ledson, M. J., Gallagher, M. J., Robinson, M., Cowperthwaite, C., Williets, T., Hart,
C. A. & Walshaw, M. J. (2002). A randomized double-blinded placebo-controlled
crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with
Burkholderia cepacia, J. Aerosol Med. 15(1): 51–57.
Lee, P. S., Gerrity, T. R., Hass, F. J. & Lourenco, R. V. (1979). A model for tracheobronchial
clearance of inhaled particles inman and a comparisonwith data, IEEE Trans. Biomed.
Eng. BME-26(11): 624–629.
Martonen, T. B., Yang, Y. & Hwang, D. (1994). Hygroscopic behaviour of secondary cigarette
smoke in human nasal passages, S.T.P. Pharma Sciences 4: 69–76.
Matsui, H., Randell, S. H., Peretti, S. W., Davis, C. W. & Boucher, R. C. (1998). Coordinated
clearance of periciliary liquid and mucus from airway surfaces, J. Clin. Invest.
102(6): 1125–1131.
Mitsakou, C., Helmis, C. & Housiadas, C. (2005). Eulerian modelling of lung deposition with
sectional representation of aerosol dynamics, J. Aerosol Sci. 36: 75–94.
Plopper, C. G., Heidsiek, J. G., Weir, A. J., St. George, J. A. & Hyde, D. M.
(1989). Tracheobronchial epithelium in the adult rhesus monkey: a quantitative
histochemical and ultrastructural study, Am. J. Anat. 184: 31–40.
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Warren, J. W., Vasilijev,
K. M., Borowitz, D., Bowman, C. M., Marshall, B. C., Marshall, S. & Smith, A. L.
(1999). Intermittent administration of inhaled tobramycin in patients with cystic
fibrosis, New Eng. J. Med. 340(1): 23–30.
Roth, A. P., Lange, C. F. & Finlay, W. H. (2003). The effect of breathing pattern on nebulizer
drug delivery, J. Aerosol Med. 16(3): 325–339.
Serafini, S. M. & Michaelson, E. D. (1977). Length and distribution of cilia in human and
canine airways, Bull. Europ. Physiopath. Resp. 13: 551–559.
Smaldone, G. C. (2002). Smart nebulizers, Respir. Care 47: 1434–1441.
Stahlhofen, W., Gebhart, J. & Heyder, J. (1980). Experimental determination of the regional
deposition of aerosol particles in the human respiratory tract, Am. Ind. Hyg. Assoc. J.
41(6): 385–398a.
Stahlhofen, W., Gebhart, J., Heyder, J. & Scheuch, G. (1983). New regional deposition data of
the human respiratory tract, J. Aerosol Sci. 14: 186–188.
Sweeney, L. G., Wang, Z., Loebenberg, R., Wong, J. P., Lange, C. F. & Finlay, W. H. (2005).
Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery,
Int. J. Pharm. 305: 180–185.
491Improving the Likelihood of Success in Trials and the Efficiency of Del very of Mucolytics and Antibiotics
www.intechopen.com
20 Will-be-set-by-IN-TECH
Tamaoki, J., Chiyotani, A., Tagaya, E., Sakai, N. & Konno, K. (1994). Effect of long term
treatment with oxitropium bromide on airway secretion in chronic brochitis and
diffuse panbronchiolitis, Thorax 49: 545–548.
Taulbee, D. B. & Yu, C. P. (1975). A theory of aerosol deposition in the human respiratory tract,
J. Appl. Physiol. 38(1): 77–85.
Wang, Z., Cheng, H. T., Roa, W. & Finlay, W. H. (2003). Farnesol for aerosol inhalation:
nebulization and activity against human lung cancer cells, J. Pharm. Sci. 6: 95–100.
Wanner, A., Salathé, M. & O’Riordan, T. G. (1996). Mucociliary clearance in the airways, Am.
J. Respir. Crit. Care Med. 154: 1868–1902.
Weibel, E. R. (1963). Morphology of the human lung, Acedemic Publishers, New York.
Widdicombe, J. G. (1997). Airway surface liquid: concepts and measurements, in D. F.
Rogers &M. I. Lethem (eds),Airway Mucus: Basic Mechanisms and Clinical Perspectives,
Birkhäuser, Basel, chapter 1, pp. 1–17.
Yeates, D. B., Sturgess, J. M., Kahi, S. R., Levison, H. & Aspin, N. (1975). Mucociliary transport
in trachea of patients with cystic fibrosis, Arch. Dis. Childhood 51: 28–33.
Yu, C. P., Hu, J. P., Yen, B. M., Spektor, D. M. & Lippmann, M. (1986). Models for mucociliary
particle clearance in lung airways, Lewis, Chelsea, Michigan, chapter 39, pp. 569–578.
492 Cystic Fibrosis – Renewed Hopes Through Research
www.intechopen.com
Cystic Fibrosis - Renewed Hopes Through Research
Edited by Dr. Dinesh Sriramulu
ISBN 978-953-51-0287-8
Hard cover, 550 pages
Publisher InTech
Published online 28, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Living healthy is all one wants, but the genetics behind creation of every human is different. As a curse or
human agony, some are born with congenital defects in their menu of the genome. Just one has to live with
that! The complexity of cystic fibrosis condition, which is rather a slow-killer, affects various organ systems of
the human body complicating further with secondary infections. That's what makes the disease so puzzling for
which scientists around the world are trying to understand better and to find a cure. Though they narrowed
down to a single target gene, the tentacles of the disease reach many unknown corners of the human body.
Decades of scientific research in the field of chronic illnesses like this one surely increased the level of life
expectancy. This book is the compilation of interesting chapters contributed by eminent interdisciplinary
scientists around the world trying to make the life of cystic fibrosis patients better.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Carlos F. Lange (2012). Improving the Likelihood of Success in Trials and the Efficiency of Delivery of
Mucolytics and Antibiotics, Cystic Fibrosis - Renewed Hopes Through Research, Dr. Dinesh Sriramulu (Ed.),
ISBN: 978-953-51-0287-8, InTech, Available from: http://www.intechopen.com/books/cystic-fibrosis-renewed-
hopes-through-research/improving-the-likelihood-of-success-in-trials-and-efficiency-of-delivery-of-mucolytics-
and-antibioti
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
